In vivo CAR (Immorna)

N/A

Report date: 2024/09/13 11:28:54

Base Information

Drug NameIn vivo CAR (Immorna)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulants

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesImmorna (Hangzhou) Biotechnology Co., Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImmorna (Hangzhou) Biotechnology Co., Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A